UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Dermatologic surgery, ISSN 1076-0512, 07/2016, Volume 42, Issue 7, pp. 804 - 827
Life Sciences & Biomedicine | Dermatology | Surgery | Science & Technology | Photochemotherapy - adverse effects | Skin Neoplasms - drug therapy | Photosensitizing Agents - therapeutic use | Photochemotherapy - methods | Humans | Pain Management | Rejuvenation | Acne Vulgaris - drug therapy | Evidence-Based Medicine | Warts - drug therapy | Consensus | Preoperative Care | Postoperative Care | Keratosis, Actinic - drug therapy | Bowen's Disease - drug therapy | Photochemotherapy - instrumentation | Photochemotherapy - standards | Carcinoma, Basal Cell - drug therapy | Pain - etiology | Cheilitis - drug therapy | Index Medicus
Journal Article
Seminars in cutaneous medicine and surgery, ISSN 1085-5629, 2011, Volume 30, Issue 4, pp. 199 - 209
Life Sciences & Biomedicine | Dermatology | Surgery | Science & Technology | Psoriasis - drug therapy | Skin Neoplasms - drug therapy | Photosensitizing Agents - therapeutic use | Humans | Acne Vulgaris - drug therapy | Aminolevulinic Acid - therapeutic use | Leishmaniasis, Cutaneous - drug therapy | Lymphoma, T-Cell, Cutaneous - drug therapy | Warts - drug therapy | Photochemotherapy | Keratosis, Actinic - drug therapy | Candidiasis - drug therapy | Bowen's Disease - drug therapy | Aminolevulinic Acid - analogs & derivatives | Tinea Capitis - drug therapy | Carcinoma, Basal Cell - drug therapy | Usage | Psoriasis | Oncology, Experimental | Melanoma | Research | Non-Hodgkin's lymphomas | T cells | Skin cancer | Hydrochloric acid | Sulfonamides | Skin | Cancer | Index Medicus
Journal Article
Photodiagnosis and photodynamic therapy, ISSN 1572-1000, 2017, Volume 19, pp. 140 - 152
Hematology, Oncology and Palliative Medicine | Internal Medicine | Cosmetic | Dermatology | Photodynamic therapy | Life Sciences & Biomedicine | Oncology | Science & Technology | Photochemotherapy - adverse effects | Scleroderma, Localized - drug therapy | Psoriasis - drug therapy | Reactive Oxygen Species - metabolism | Photosensitizing Agents - therapeutic use | Photochemotherapy - methods | Humans | Aminolevulinic Acid - pharmacology | Protoporphyrins - pharmacology | Acne Vulgaris - drug therapy | Skin Diseases - drug therapy | Aminolevulinic Acid - therapeutic use | Rejuvenation - physiology | Warts - drug therapy | Photosensitizing Agents - administration & dosage | Collagen - biosynthesis | Protoporphyrins - therapeutic use | Port-Wine Stain - drug therapy | Procollagen - biosynthesis | Skin - drug effects | Skin Temperature | Skin diseases | Skin | Photochemotherapy | Collagen | Melanoma | Cancer | Cell death | Heme | Hemoglobin synthesis | Skin cancer | Index Medicus | cosmetic | dermatology
Journal Article
4.
Full Text
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 18, pp. 4963 - 4966
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Immunopathology | Biological and medical sciences | Medical sciences | Immunodeficiencies. Immunoglobulinopathies | Immunodeficiencies | Immunologic Deficiency Syndromes - pathology | Humans | Middle Aged | Male | Granulocyte Precursor Cells - drug effects | Anti-HIV Agents - administration & dosage | Dose-Response Relationship, Drug | Warts - pathology | Bone Marrow Diseases - drug therapy | Adult | Anti-HIV Agents - therapeutic use | Female | Immunologic Deficiency Syndromes - blood | Receptors, CXCR4 - genetics | Warts - genetics | Drug Administration Schedule | Heterocyclic Compounds - administration & dosage | Receptors, CXCR4 - antagonists & inhibitors | Anti-HIV Agents - adverse effects | Warts - blood | Bone Marrow Diseases - pathology | Warts - drug therapy | Granulocyte Precursor Cells - pathology | Leukopenia - pathology | Primary Immunodeficiency Diseases | Heterocyclic Compounds - adverse effects | Anti-HIV Agents - pharmacokinetics | Leukopenia - complications | Immunologic Deficiency Syndromes - genetics | Heterocyclic Compounds - pharmacokinetics | Leukopenia - drug therapy | Aged | Immunologic Deficiency Syndromes - drug therapy | Heterocyclic Compounds - therapeutic use | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations | Brief Report | Phagocytes, Granulocytes, and Myelopoiesis
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 2, pp. 163 - 170
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Immunologic Deficiency Syndromes - pathology | Primary Myelofibrosis - drug therapy | Receptors, CXCR4 - antagonists & inhibitors | Humans | Middle Aged | Male | Primary Myelofibrosis - pathology | Warts - drug therapy | Bone Marrow Examination | Warts - pathology | Phenotype | Neoplasms, Squamous Cell - genetics | Bone Marrow - pathology | Neoplasms, Squamous Cell - drug therapy | Fatal Outcome | Receptors, CXCR4 - genetics | Immunologic Deficiency Syndromes - drug therapy | Heterocyclic Compounds - therapeutic use | Immunological deficiency syndromes | Genetic aspects | Research | Gene mutations | Drug therapy | Chemokine receptors | Laboratories | Reconstructive surgery | Infections | Hypogammaglobulinemia | Human papillomavirus | Granulocytes | Granulocyte colony-stimulating factor | Lymphocytes | Surgery | Bone marrow | Colony-stimulating factor | Drug dosages | Age | Neutropenia | Thrombocytopenia | Immunoglobulins | Myelofibrosis | Bacterial infections | Anemia | Neutrophils | Immunodeficiency | FDA approval | Patients | Lymphoma | CXCR4 protein | Quality of life | Warts | Ostomy | Chemotherapy | Infectious diseases | Mutation | Leukocytes (granulocytic) | Chemokines | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 01/2020, Volume 82, Issue 1, pp. 202 - 212
nonmelanoma skin cancer | vaccine | viral warts | neoplasia | human papillomavirus | Life Sciences & Biomedicine | Dermatology | Science & Technology | Skin Neoplasms - drug therapy | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - therapeutic use | Vulvar Neoplasms - drug therapy | Humans | Cervical Intraepithelial Neoplasia - drug therapy | Respiratory Tract Infections - drug therapy | Uterine Cervical Neoplasms - drug therapy | Warts - drug therapy | Neoplasms - drug therapy | Cancer Vaccines - therapeutic use | Carcinoma, Squamous Cell - drug therapy | Anus Neoplasms - drug therapy | Carcinoma, Basal Cell - drug therapy | Papillomavirus Infections - drug therapy | Female | Index Medicus
Journal Article
The Journal of dermatological treatment, ISSN 0954-6634, 12/2009, Volume 20, Issue 6, pp. 328 - 335
5-fluorouracil | Actinic keratosis | skin cancer | keratoacanthoma | psoriasis | vitiligo | topical therapy | warts | Warts | Topical therapy | Vitiligo | Psoriasis | Keratoacanthoma | Skin cancer | Life Sciences & Biomedicine | Dermatology | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Pigmentary diseases of the skin | Infectious diseases | Psoriasis. Parapsoriasis. Lichen | Viral diseases | Biological and medical sciences | Medical sciences | Human viral diseases | Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye | Psoriasis - drug therapy | Skin Neoplasms - drug therapy | Dermatologic Agents - administration & dosage | Humans | Skin Diseases - drug therapy | Treatment Outcome | Clinical Trials as Topic | Dermatologic Agents - therapeutic use | Administration, Cutaneous | Warts - drug therapy | Randomized Controlled Trials as Topic | Nail Diseases - drug therapy | Fluorouracil - therapeutic use | Carcinoma, Squamous Cell - drug therapy | Fluorouracil - administration & dosage | Keratosis, Actinic - drug therapy | Carcinoma, Basal Cell - drug therapy | Keratoacanthoma - drug therapy | Vitiligo - drug therapy | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 02/2013, Volume 24, Issue 2, pp. 530 - 537
BRAF inhibitor | side effects | MEK inhibitor | cutaneous squamous cell carcinoma | photosensitivity | Photosensitivity | Side effects | Cutaneous squamous cell carcinoma | Life Sciences & Biomedicine | Oncology | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Dermatology | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Skin involvement in other diseases. Miscellaneous. General aspects | Antineoplastic agents | Photosensitivity Disorders - chemically induced | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Female | Retrospective Studies | Imidazoles - therapeutic use | Skin Diseases - chemically induced | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Keratoacanthoma - chemically induced | Keratosis, Actinic - chemically induced | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Indoles - adverse effects | Sulfonamides - therapeutic use | Melanoma - drug therapy | Sulfonamides - adverse effects | Indoles - therapeutic use | Pyridones - therapeutic use | Warts - chemically induced | Pyridones - adverse effects | Index Medicus
Journal Article